HRP20231172T1 - Spojevi za upotrebu u liječenju alzheimerove bolesti kod apoe4+/+ pacijenata - Google Patents
Spojevi za upotrebu u liječenju alzheimerove bolesti kod apoe4+/+ pacijenata Download PDFInfo
- Publication number
- HRP20231172T1 HRP20231172T1 HRP20231172TT HRP20231172T HRP20231172T1 HR P20231172 T1 HRP20231172 T1 HR P20231172T1 HR P20231172T T HRP20231172T T HR P20231172TT HR P20231172 T HRP20231172 T HR P20231172T HR P20231172 T1 HRP20231172 T1 HR P20231172T1
- Authority
- HR
- Croatia
- Prior art keywords
- patient
- apoe4
- compound
- formula
- image
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 21
- 208000024827 Alzheimer disease Diseases 0.000 title claims 7
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108700028369 Alleles Proteins 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000006186 oral dosage form Substances 0.000 claims 3
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229960003570 tramiprosate Drugs 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 238000003205 genotyping method Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Engineering & Computer Science (AREA)
Claims (9)
1. Spoj odabran od
spoja formule I:
[image]
i
spoja formule II:
[image]
pri čemu je svaki od AA1 i AA2 neovisno odabrana aminokiselina;
za upotrebu u postupku liječenja Alzheimerove bolesti u pod-populaciji pacijenata koji nose dvije kopije alela ApoE4.
2. Spoj odabran od:
tramiprozata,
spoja formule I:
[image]
i
spoja formule II:
[image]
pri čemu je svaki od AA1 i AA2 neovisno odabrana aminokiselina,
za upotrebu u postupku liječenja Alzheimerove bolesti, pri čemu postupak obuhvaća:
(a) utvrđivanje je li pacijent ApoE4 +/+ pacijent, pri čemu je ApoE4 +/+ pacijent, pacijent koji nosi dvije kopije alela ApoE4; i
(b) davanje spoja samo ako je pacijent ApoE4 +/+ pacijent.
3. Spoj za upotrebu prema zahtjevu 1 ili zahtjevu 2, naznačen time što spoj ima formulu:
[image]
4. Farmaceutski pripravak za upotrebu u postupku liječenja Alzheimerove bolesti u pod-populaciji pacijenata koji nose dvije kopije alela ApoE4, pri čemu pripravak sadrži farmaceutski prihvatljiv nosač i spoj odabran od
spoja formule I:
[image]
i
spoja formule II:
[image]
pri čemu je svaki od AA1 i AA2 neovisno odabrana aminokiselina, i pri čemu je farmaceutski pripravak oralni oblik doziranja.
5. Farmaceutski pripravak za upotrebu u postupku liječenja Alzheimerove bolesti, pri čemu pripravak sadrži farmaceutski prihvatljiv nosač i spoj odabran od
tramiprozata,
spoja formule I:
[image]
i
spoja formule II:
[image]
pri čemu je svaki od AA1 i AA2 neovisno odabrana aminokiselina, i pri čemu je farmaceutski pripravak oralni oblik doziranja,
pri čemu postupak obuhvaća:
(a) utvrđivanje je li pacijent ApoE4 +/+ pacijent, pri čemu je ApoE4 +/+ pacijent, pacijent koji nosi dvije kopije alela ApoE4; i
(b) davanje spoja samo ako je pacijent ApoE4 +/+ pacijent.
6. Farmaceutski pripravak za upotrebu prema zahtjevu 4 ili zahtjevu 5, naznačen time što spoj ima formulu:
[image]
7. Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 4-6, naznačen time što je oralni oblik doziranja odabran između tableta, pastila, vodenih ili uljnih suspenzija, granula, praškova, emulzija, kapsula, sirupa, eliksira, hrane, i mješavine hrane.
8. Spoj za upotrebu prema bilo kojem od zahtjeva 1-3 ili farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 4-7, pri čemu je navedeno liječenje Alzheimerove bolesti smanjenje kognitivnog pada povezanog s Alzheimerovom bolešću.
9. Spoj za upotrebu prema bilo kojem od zahtjeva 1-3 ili farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 4-7, pri čemu postupak liječenja obuhvaća korak genotipizacije pacijenta kojeg treba liječiti prije primjene spoja radi određivanja ima li pacijent dvije kopije alela ApoE4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968595P | 2014-03-21 | 2014-03-21 | |
| EP15764560.7A EP3119911B1 (en) | 2014-03-21 | 2015-03-23 | Compounds for use in treating alzheimer's disease in apoe4+/+ patients |
| PCT/US2015/022058 WO2015143447A2 (en) | 2014-03-21 | 2015-03-23 | Methods for treating neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231172T1 true HRP20231172T1 (hr) | 2024-01-05 |
Family
ID=54145492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231172TT HRP20231172T1 (hr) | 2014-03-21 | 2015-03-23 | Spojevi za upotrebu u liječenju alzheimerove bolesti kod apoe4+/+ pacijenata |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10471029B2 (hr) |
| EP (2) | EP4289820A3 (hr) |
| JP (4) | JP6588962B2 (hr) |
| KR (2) | KR102448386B1 (hr) |
| CN (1) | CN106170563A (hr) |
| AU (1) | AU2015230972B2 (hr) |
| CA (1) | CA2941415A1 (hr) |
| DK (1) | DK3119911T3 (hr) |
| ES (1) | ES2960625T3 (hr) |
| FI (1) | FI3119911T3 (hr) |
| HR (1) | HRP20231172T1 (hr) |
| HU (1) | HUE063369T2 (hr) |
| LT (1) | LT3119911T (hr) |
| PL (1) | PL3119911T3 (hr) |
| PT (1) | PT3119911T (hr) |
| RS (1) | RS64744B1 (hr) |
| SI (1) | SI3119911T1 (hr) |
| WO (1) | WO2015143447A2 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2952727T3 (es) * | 2015-09-10 | 2023-11-03 | Alzheon Inc | Tratamiento de la enfermedad de Alzheimer en una población de pacientes particular |
| US20200196637A1 (en) * | 2016-07-13 | 2020-06-25 | Mitos Co., Ltd. | Composition for prevention or treatment of mild cognitive impairment or dementia containing hydrogen as active ingredient |
| CN108623501B (zh) | 2017-03-21 | 2022-04-19 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸衍生物及其用途 |
| CN110003058B (zh) | 2018-01-04 | 2022-01-25 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途 |
| CN110668980A (zh) * | 2018-07-03 | 2020-01-10 | 浙江京新药业股份有限公司 | 一种2-取代的高牛磺酸衍生物 |
| JP2021533128A (ja) * | 2018-08-01 | 2021-12-02 | アルツェオン・インコーポレーテッド | 神経変性障害を治療するための方法 |
| MX2021001273A (es) * | 2018-08-01 | 2021-07-15 | Alzheon Inc | Métodos para tratar trastornos neurodegenerativos. |
| CN111170901A (zh) * | 2018-11-13 | 2020-05-19 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途 |
| BR112021025504A2 (pt) * | 2019-06-17 | 2022-04-26 | Alzheon Inc | Métodos para tratar distúrbios neurodegenerativos |
| CN116059192A (zh) | 2019-11-13 | 2023-05-05 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| WO2023212289A1 (en) | 2022-04-28 | 2023-11-02 | Alzheon, Inc. | Tramiprosate for treating apoe4-related diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| DE625212T1 (de) * | 1992-10-13 | 2000-11-02 | Univ Durham | Verfahren zum entdecken von krankheit von alzheimer. |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20060079578A1 (en) * | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20070010573A1 (en) | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| CN1867795B (zh) | 2003-08-11 | 2010-12-08 | 加州理工学院 | 微流体的大规模集成 |
| WO2009019534A2 (en) | 2006-10-12 | 2009-02-12 | Bellus Health (International) Limited | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
| JP5292300B2 (ja) | 2006-11-24 | 2013-09-18 | エーシー イミューン ソシエテ アノニム | 例えばアルツハイマー病のようなアミロイドまたはアミロイド様タンパク質に関連する疾患の治療のためのｎ−（メチル）−１ｈ−ピラゾール−３−アミン誘導体、ｎ−（メチル）−ピリジン−２−アミン誘導体、およびｎ−（メチル）−トリゾール−２−アミン誘導体 |
| WO2012006329A2 (en) * | 2010-07-06 | 2012-01-12 | Genomind, Llc | Apoe4 and apoj biomarker-based prevention and treatment of dementia |
| EP2605655B1 (en) | 2010-08-19 | 2018-10-24 | Buck Institute for Age Research | Methods of treating mild cognitive impairment (mci) and related disorders |
| PT2994160T (pt) | 2013-05-06 | 2019-08-07 | Baxalta Inc | Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada |
| RU2724190C2 (ru) * | 2014-02-08 | 2020-06-23 | Дженентек, Инк. | Способы лечения болезни альцгеймера |
| ES2952727T3 (es) | 2015-09-10 | 2023-11-03 | Alzheon Inc | Tratamiento de la enfermedad de Alzheimer en una población de pacientes particular |
| US20180250249A1 (en) | 2016-02-02 | 2018-09-06 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular population |
-
2015
- 2015-03-23 HR HRP20231172TT patent/HRP20231172T1/hr unknown
- 2015-03-23 PT PT157645607T patent/PT3119911T/pt unknown
- 2015-03-23 FI FIEP15764560.7T patent/FI3119911T3/fi active
- 2015-03-23 EP EP23189240.7A patent/EP4289820A3/en active Pending
- 2015-03-23 LT LTEPPCT/US2015/022058T patent/LT3119911T/lt unknown
- 2015-03-23 RS RS20230993A patent/RS64744B1/sr unknown
- 2015-03-23 DK DK15764560.7T patent/DK3119911T3/da active
- 2015-03-23 WO PCT/US2015/022058 patent/WO2015143447A2/en active Application Filing
- 2015-03-23 JP JP2017501145A patent/JP6588962B2/ja active Active
- 2015-03-23 CA CA2941415A patent/CA2941415A1/en active Pending
- 2015-03-23 CN CN201580015086.8A patent/CN106170563A/zh active Pending
- 2015-03-23 AU AU2015230972A patent/AU2015230972B2/en active Active
- 2015-03-23 HU HUE15764560A patent/HUE063369T2/hu unknown
- 2015-03-23 SI SI201531967T patent/SI3119911T1/sl unknown
- 2015-03-23 KR KR1020167027090A patent/KR102448386B1/ko active IP Right Grant
- 2015-03-23 ES ES15764560T patent/ES2960625T3/es active Active
- 2015-03-23 EP EP15764560.7A patent/EP3119911B1/en active Active
- 2015-03-23 PL PL15764560.7T patent/PL3119911T3/pl unknown
- 2015-03-23 US US15/127,565 patent/US10471029B2/en active Active
- 2015-03-23 KR KR1020227033161A patent/KR102645633B1/ko active IP Right Grant
-
2019
- 2019-01-29 JP JP2019012873A patent/JP2019065044A/ja not_active Withdrawn
- 2019-09-13 US US16/570,487 patent/US20200101031A1/en not_active Abandoned
-
2020
- 2020-04-02 JP JP2020066670A patent/JP2020109123A/ja not_active Withdrawn
-
2022
- 2022-07-29 US US17/877,380 patent/US20230087041A1/en active Pending
- 2022-08-22 JP JP2022131705A patent/JP2022159555A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN106170563A (zh) | 2016-11-30 |
| JP2017511377A (ja) | 2017-04-20 |
| AU2015230972B2 (en) | 2021-05-27 |
| PT3119911T (pt) | 2023-11-03 |
| US20200101031A1 (en) | 2020-04-02 |
| KR102448386B1 (ko) | 2022-09-28 |
| EP4289820A3 (en) | 2024-03-13 |
| RS64744B1 (sr) | 2023-11-30 |
| DK3119911T3 (da) | 2023-10-30 |
| EP3119911B1 (en) | 2023-08-09 |
| SI3119911T1 (sl) | 2023-12-29 |
| US20230087041A1 (en) | 2023-03-23 |
| EP4289820A2 (en) | 2023-12-13 |
| WO2015143447A3 (en) | 2016-01-14 |
| KR20160128391A (ko) | 2016-11-07 |
| FI3119911T3 (fi) | 2023-09-27 |
| AU2015230972A1 (en) | 2016-09-15 |
| JP2020109123A (ja) | 2020-07-16 |
| CA2941415A1 (en) | 2015-09-24 |
| KR102645633B1 (ko) | 2024-03-11 |
| HUE063369T2 (hu) | 2024-01-28 |
| EP3119911A4 (en) | 2017-12-13 |
| ES2960625T3 (es) | 2024-03-05 |
| US20170172952A1 (en) | 2017-06-22 |
| EP3119911A2 (en) | 2017-01-25 |
| US10471029B2 (en) | 2019-11-12 |
| JP2022159555A (ja) | 2022-10-17 |
| LT3119911T (lt) | 2023-10-10 |
| PL3119911T3 (pl) | 2024-01-22 |
| KR20220136476A (ko) | 2022-10-07 |
| JP6588962B2 (ja) | 2019-10-09 |
| WO2015143447A2 (en) | 2015-09-24 |
| JP2019065044A (ja) | 2019-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231172T1 (hr) | Spojevi za upotrebu u liječenju alzheimerove bolesti kod apoe4+/+ pacijenata | |
| HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
| PH12017500479B1 (en) | Liquid inhalation formulation comprising rpl554 | |
| WO2017083304A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| BR112017022101A2 (pt) | composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo | |
| JP2017511377A5 (hr) | ||
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| NZ741318A (en) | Compound for treating or preventing hyperuricemia or gout | |
| SG10201810404XA (en) | Combination comprising a glucocorticoid and edo-s101 | |
| WO2011151722A3 (en) | Methods and compositions for oral pharmaceutical therapy | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| BR112017001695A2 (pt) | terapia de combinação | |
| HRP20161796T1 (hr) | Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice | |
| JP2016069317A5 (ja) | 腎不全進行抑制剤、腎不全予防剤、尿毒症治療剤、インドキシル硫酸産生阻害剤、心血管系疾患予防剤、及び食品組成物 | |
| SG11202100369WA (en) | Pharmaceutical dosage form which can be administered orally and has modified release | |
| JP2019500379A5 (hr) | ||
| WO2015017423A3 (en) | Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture | |
| BR112018068784A2 (pt) | método para o tratamento de leucemia | |
| MX2018003890A (es) | Composiciones farmaceuticas que contienen un relajante muscular y un antiinflamatorio no esteroideo (aine). | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| WO2017067664A9 (en) | Oxa-diazaspiro compounds having activity against pain | |
| PH12016501026A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor | |
| MD3439637T2 (ro) | Procedeu pentru formulări solide de mesalazină | |
| ZA202106071B (en) | Pharmaceutical oral dosage forms for treatment of metabolic disorders and related diseases through orchestrated release of enterokines |